Screening for Hepatitis B Surface Antigen before Chemotherapy: Current Practice and Opportunities for Improvement | Zendy

R. Lee | Zendy; Kim N. Vu | Zendy; Chaim M. Bell | Zendy; Lisa K. Hicks | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Screening for Hepatitis B Surface Antigen before Chemotherapy: Current Practice and Opportunities for Improvement

Author(s) -

R. Lee,

Kim N. Vu,

Chaim M. Bell,

Lisa K. Hicks

Publication year - 2010

Publication title -

current oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.053

H-Index - 51

eISSN - 1718-7729

pISSN - 1198-0052

DOI - 10.3747/co.v17i6.653

Subject(s) - medicine , antigen , hepatitis b , current (fluid) , immunology , virology , family medicine , engineering , electrical engineering

Hepatitis B virus (hbv) reactivation is a recognized complication of chemotherapy. The U.S. Centers for Disease Control and Prevention recommend that all patients be screened for the hbv surface antigen (hbsag) before chemotherapy. We sought to determine the frequency of hbsag testing before chemotherapy at our hospital and to increase the frequency of testing to more than 90% of patients starting chemotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research